help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ramirez, G.
Right arrow Articles by Brueggemeyer, C. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ramirez, G.
Right arrow Articles by Brueggemeyer, C. D.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*CAPTOPRIL
*EPINEPHRINE
*HYDROCORTISONE
*POTASSIUM

Journal of Clinical Endocrinology & Metabolism, Vol 66, 46-50, Copyright © 1988 by Endocrine Society

ARTICLES

Acute effect of captopril on aldosterone secretory responses to endogenous or exogenous adrenocorticotropin

G Ramirez, A Ganguly and CD Brueggemeyer
Department of Internal Medicine, James A. Haley Veterans Administration Hospital, Tampa, Florida 33612.

The aldosterone secretory response to Captopril (12.5 mg, orally) was studied in five normal men. Endogenous ACTH and epinephrine secretion was stimulated by the induction of hypoglycemia. Normally this stimulus increases plasma cortisol, GH, aldosterone, and PRA. Administration of captopril resulted in a blunted plasma aldosterone response to hypoglycemia, but no concomitant blunting of the plasma cortisol response. The responses of other hormones, with the exception of PRA, were not affected. When exogenous ACTH was administered to the same men with and without captopril, the plasma aldosterone response was again blunted by captopril, while the plasma cortisol response was unaffected. We conclude that angiotensin II may be required for ACTH to stimulate aldosterone secretion. Alternatively, the possibility that captopril may selectively inhibit aldosterone secretion at the adrenal cellular level cannot be excluded.


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
E. Arvat, L. Di Vito, F. Lanfranco, M. Maccario, C. Baffoni, R. Rossetto, G. Aimaretti, F. Camanni, and E. Ghigo
Stimulatory Effect of Adrenocorticotropin on Cortisol, Aldosterone, and Dehydroepiandrosterone Secretion in Normal Humans: Dose-Response Study
J. Clin. Endocrinol. Metab., September 1, 2000; 85(9): 3141 - 3146.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. C. Clapham and N. C. Turner
Effects of the Glucocorticoid II Receptor Antagonist Mifepristone on Hypertension in the Obese Zucker Rat
J. Pharmacol. Exp. Ther., September 1, 1997; 282(3): 1503 - 1508.
[Abstract] [Full Text]

Home page
 HypertensionHome page
P. Gupta, R. Franco-Saenz, and P. J. Mulrow
Locally Generated Angiotensin II in the Adrenal Gland Regulates Basal, Corticotropin-, and Potassium-Stimulated Aldosterone Secretion
Hypertension, March 1, 1995; 25(3): 443 - 448.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1988 by The Endocrine Society